Botulinum Toxin for the Treatment of Involuntary Movement Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001208|
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : June 21, 2018
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Primary Completion Date :||No date given|
|Estimated Study Completion Date :||October 30, 2019|
Hott JS, Dalakas MC, Sung C, Hallett M, Youle RJ. Skeletal muscle-specific immunotoxin for the treatment of focal muscle spasm. Neurology. 1998 Feb;50(2):485-91.
Karp BI, Cole RA, Cohen LG, Grill S, Lou JS, Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology. 1994 Jan;44(1):70-6.